KRAS and neoplasm: To assess the impact of the C118 substitutions on oncogenic KRAS signaling in vivo, we subcutaneously implanted KRaslox KRASMUT MEFs expressing KRASG12V, KRASG12V/C118S, or KRASG12V/C118D into mice and assessed their in vivo tumor growth and survival rate.